Sagimet Biosciences to Present at Three Key Investor Conferences in March
Event summary
- Sagimet Biosciences will participate in three investor conferences in March 2026, including TD Cowen, Leerink Global Healthcare, and The Citizens Life Sciences Conference.
- Fireside chats scheduled for March 2, March 9, and March 10, 2026, with replays available for 90 days.
- Denifanstat, Sagimet’s lead candidate, met all primary endpoints in Phase 2b FASCINATE-2 trial for MASH and Phase 3 trial in China for acne.
- Phase 1 PK trial ongoing for denifanstat and resmetirom combination for cirrhotic MASH patients.
- TVB-3567, a second FASN inhibitor, in Phase 1 trial for acne.
The big picture
Sagimet Biosciences is actively engaging with the investment community amid a critical phase of its clinical pipeline. The company’s participation in multiple high-profile conferences underscores its focus on communicating trial progress and strategic direction. The broader biopharmaceutical sector is closely watching the development of novel therapeutics targeting metabolic and fibrotic pathways, particularly in high-unmet-need areas like MASH and acne.
What we're watching
- Clinical Progress
- How the Phase 1 PK trial results for the denifanstat and resmetirom combination will impact the development timeline for cirrhotic MASH patients.
- Market Positioning
- Whether Sagimet can leverage positive trial data to strengthen its position in the competitive MASH and acne treatment markets.
- Investor Sentiment
- The pace at which investor interest and potential partnerships develop following the upcoming conference presentations.